As Generics Wave Builds, Novo Nordisk Cuts Ozympic, Vigoy Prices
In a bid to compete with cheaper generics, Danish drugmaker Novo Nordisk on Monday announced a 36 percent and 48 percent price cut for its injectable semaglutide brands Ozympic and Vigovi in India, respectively. However, senior executives told Business Standard that the company is not planning a similar move for its oral semaglutide brand, Rebelsos. … Read more
